October 2020 – pharma.markets

Merck Collaborates with Mammoth Biosciences to Scale New SARS-CoV-2 Test

29/10/2020 MaP 0

Merck today announced a collaboration with Mammoth Biosciences Inc. for the development, scale-up and commercial production of Mammoth’s CRISPR-based SARS CoV-2 diagnostic test. Merck, a […]

Coronavirus: EU Commission lists key steps for effective vaccination strategies and vaccines deployment

16/10/2020 MaP 0

As Europe learns to live with the pandemic, the development and swift global deployment of safe and effective vaccines against COVID-19 remains an essential element […]

Pfizer and BioNTech Announce New England Journal of Medicine Publication of Phase 1 Data on Lead mRNA Vaccine Candidate BNT162b2 Against COVID-19

14/10/2020 MaP 0

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that preliminary, peer-reviewed data from the Phase 1 portion of their ongoing U.S. study […]

BioNTech to Present Data from BNT311 (GEN1046) and BNT131 (SAR441000) Programs at SITC 35th Annual Meeting

14/10/2020 MaP 0

BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today announced that results from three clinical and preclinical studies have been accepted for presentation at the […]

New Clinical Trial for a COVID-19 Vaccine Authorised in Germany

02/10/2020 MaP 0

The Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines has authorised another Phase-1 clinical trial of a vaccine against COVID-19 in Germany. The new vaccine candidate […]

BioNTech and Pfizer Announce Nature Publication of German Phase 1/2 Study Data from mRNA-based Vaccine Candidate BNT162b1 Against SARS-CoV-2

01/10/2020 MaP 0

BioNTech SE (Nasdaq: BNTX) and Pfizer Inc. (NYSE: PFE) today announced that preliminary, peer-reviewed data from their ongoing German Phase 1/2 Study of BNT162b1 were […]